ProGen Search
Intelligence Vault
Radiopharma

Ac-225 Supply and Demand Outlook: Preview Report

A free preview of how ProGen's bottom-up outlook for actinium-225 is built, down to the inputs it carries. It traces supply across six production routes, from feedstock to qualified material, sets it against demand from the clinical pipeline across ten regions, and shows how economics, scenarios and the evidence base fit together. Results are reserved for buyers.

PDF9 pagesPublished November 2026Free

2026 to 2036 · Research cut-off: 29 October 2026

What this report answers

  • Which production routes supply Ac-225, and how does each move from feedstock to qualified material?
  • How is demand from the clinical pipeline built, region by region?
  • Why read demand four ways rather than as a single number?
  • Which assumptions move the supply and demand balance?
  • What does a buyer of the full outlook receive?

280 regional patient pools

28 disease and treatment-history pools, each carried across ten regions mapped from 187 countries.

1,024 simulated paths

In the main run, monthly from 2026 to 2036.

What the analysis establishes

Six production routes

Th-229 generator, Ra-226 proton cyclotron, Ra-226 photonuclear, Th-232 direct spallation, Th-232 Ra-225 harvest, and reactor radium and other routes. Each is traced from its feedstock through shared capacity to qualification and GMP, tested across ten regions and four product classes.

Demand from the clinical pipeline

93 seed records resolved into 90 programs, with 84 approval or label events, 52 molecular targets and 106 non-commercial program rows, flowing month by month through 28 disease pools in each of ten regions. The preview lists the inputs every program, treatment cycle and patient pool carries. Demand is read four ways: Desired, Economic, Operational and Fulfilled.

Economics at three levels

Break-even arithmetic for the isotope producer, the drug manufacturer and the treating provider, set out as scenario arithmetic and never as an observed price.

Scenarios and sensitivities

Three operating cases, four anchor worlds and a set of paired sensitivity cases, run monthly to 2036, with 1,024 simulated paths in the main run and headline readings at 2028, 2031 and 2036. The preview shows the structure; values are withheld.

Built to your decision

Each edition is scoped to the decision in front of you, whether a program, a portfolio, a supply agreement or an investment thesis, and quoted on request.

About this intelligence

More than 1,600 evidence records from about 1,000 cited public sources, and more than 3,800 documented assumptions, each with a basis, a unit and a cut date. Sources include public registries, regulator records, company filings and disclosures. Other sources are proprietary ProGen intelligence sources. Evidence is current to 29 October 2026.

Investors testing whether a valuation depends on Ac-225 staying scarce. Developers of alpha-emitter programs planning supply and second sources. Corporate development teams assessing producers, licenses or partnerships. Producers, CDMOs and the business development teams selling into them.

Contents

  • Why an Ac-225 outlook
  • The questions it answers
  • How the outlook is built
  • Supply: six production routes
  • Qualification and GMP
  • Ten regions
  • Demand: the program universe and its inputs
  • Demand: from pipeline to patients
  • Economics at three levels
  • The horizon
  • Scenarios
  • What moves the result
  • The evidence base
  • What a buyer receives

Production routes covered

Th-229 generator, Ra-226 proton cyclotron, Ra-226 photonuclear, Th-232 direct spallation, Th-232 Ra-225 harvest, Reactor radium and other routes

Free report

The full 9-page briefing is free. Tell us where to send it and it downloads immediately.

Going deeper

Ac-225 Supply and Demand Outlook

Built to your question and quoted individually: supply by production route against demand from the clinical pipeline.

See the analysis →

Related analysis